Level C· Early human research exploring benefitsProspective StudyPubMed

Adipose-derived Human Perivascular Stem Cells May Improve Achilles Tendon Healing in Rats.

Devana SK., Kelley BV., McBride OJ., Kabir N., Jensen AR., Park SJ.

Prospective Study on Tendon Injury, Chronic Wound, published in Clin Orthop Relat Res (2018) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Clin Orthop Relat Res (2018)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
30179944
PMCID
PMC6259872
DOI
10.1097/CORR.0000000000000461
Citations
14

Abstract (original English)

Background Achilles tendon rupture is a common injury and the best treatment option remains uncertain between surgical and nonoperative methods. Biologic approaches using multipotent stem cells such as perivascular stem cells pose a possible treatment option, although there is currently a paucity of evidence regarding their clinical therapeutic use. Questions/purposes The purpose of this study was to determine whether injected perivascular stem cells (PSCs) would (1) improve histologic signs of tendon healing (such as percent area of collagen); and (2) improve biomechanical properties (peak load or stiffness) in a rat model of Achilles tendon transection. Methods Two subtypes of PSCs were derived from human adipose tissue: pericytes (CD146CD34CD45CD31) and adventitial cells (CD146CD34CD45CD31). Thirty-two athymic rats underwent right Achilles transection and were randomized to receive injection with saline (eight tendons), hydrogel (four tendons), pericytes in hydrogel (four tendons), or adventitial cells in hydrogel (eight tendons) 3 days postoperatively with the left serving as an uninjured control. Additionally, a subset of pericytes was labeled with CM-diI to track cell viability and localization. At 3 weeks, the rats were euthanized, and investigators blinded to treatment group allocation evaluated tendon healing by peak load and stiffness using biomechanical testing and p

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Achilles TendonAdipose TissueAdventitiaAnimalsBiomarkersBiomechanical PhenomenaCells, CulturedCollagenDisease Models, AnimalHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research